Stroke Trials Registry

Ebselen
Harmokisane

Action
Antioxidant (seleno-organic compound with antioxidant activity through a glutathione peroxidase-like action)

Status
Multicenter acute stroke trial reported January 1998 (see below). Phase II trial from Japan showed no significant difference in primary outcome measure. Trial of ebselen after subarachnoid hemorrhage showed no difference in incidence of clinically diagnosed delayed ischemia, but improvement in ebselen-treated patients.

Trial(s)
= Ongoing
= Completed

Ebselen in Acute Ischemic Stroke

Ebselen Trial - Phase III

Web Links and Publications

Daiichi Pharmaceutical Co. (Japan) Web Site.

Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial.
Cerebrovasc Dis. 1999 Mar-Apr;9(2):112-8.

Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage.
Neurosurgery 1998 Feb;42(2):269-77

UID: 16